FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173977892> ?p ?o ?g. }

• W3173977892 endingPage "4556" @default.
• W3173977892 startingPage "4549" @default.
• W3173977892 abstract "Radium-223 is an alpha-emitting radionuclide associated with overall survival (OS) improvement in metastatic castration-resistant prostate cancer (mCRPC). External beam radiotherapy (EBRT) to prostate extends OS in men with metastatic hormone-sensitive prostate cancer (mHSPC) limited to less than 4 metastases. We hypothesized that combination radium-223 + pelvic EBRT could safely deliver maximal radiotherapy doses to primary and metastatic prostate cancer and may improve disease control.Thirty patients with de novo bone metastatic mHSPC who had commenced androgen deprivation therapy (ADT) and docetaxel were recruited to this single-arm, open-label, prospective clinical trial: Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 (ADRRAD; for new presentation T1-4 N0-1 M1B adenocarcinoma of prostate). Study treatments were: ADT, 6 cycles of radium-223 q28 days, conventionally fractionated prostate radiotherapy (74 Gy) and simultaneous integrated boost to pelvic lymph nodes (60 Gy).No grade 4/5 toxicity was observed. Three patients experienced grade 3 leukopenia, and 1 each experienced grade 3 neutropenia and thrombocytopenia; all were asymptomatic. One patient each experienced grade 3 dysuria and grade 3 urinary infection. No grade 3 gastrointestinal (GI) toxicity was observed. On treatment completion, there was a signal of efficacy; 24 (80%) patients had whole-body MRI evidence of tumor response or stability. Twenty-seven (90%) patients showed a reduction in alkaline phosphatase (ALP) compared with pretreatment levels. Median progression-free survival was 20.5 months.This is the first trial of combination ADT, radium-223, and EBRT to pelvis, post docetaxel. The combination was safe, with an efficacy signal. Multicenter randomized controlled trials (RCT) are warranted." @default.
• W3173977892 created "2021-07-05" @default.
• W3173977892 creator A5001842263 @default.
• W3173977892 creator A5014617881 @default.
• W3173977892 creator A5027261034 @default.
• W3173977892 creator A5032708784 @default.
• W3173977892 creator A5034681607 @default.
• W3173977892 creator A5044156541 @default.
• W3173977892 creator A5047739980 @default.
• W3173977892 creator A5048994559 @default.
• W3173977892 creator A5063560933 @default.
• W3173977892 creator A5076875343 @default.
• W3173977892 date "2021-06-29" @default.
• W3173977892 modified "2023-09-24" @default.
• W3173977892 title "Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer" @default.
• W3173977892 cites W1242972575 @default.
• W3173977892 cites W2000201793 @default.
• W3173977892 cites W2016905895 @default.
• W3173977892 cites W2055346449 @default.
• W3173977892 cites W2066845679 @default.
• W3173977892 cites W2097539177 @default.
• W3173977892 cites W2117511763 @default.
• W3173977892 cites W2120292596 @default.
• W3173977892 cites W2137282952 @default.
• W3173977892 cites W2138809580 @default.
• W3173977892 cites W2141454098 @default.
• W3173977892 cites W2144827656 @default.
• W3173977892 cites W2146599397 @default.
• W3173977892 cites W2148643283 @default.
• W3173977892 cites W2150865892 @default.
• W3173977892 cites W2166918329 @default.
• W3173977892 cites W2167331614 @default.
• W3173977892 cites W2168242827 @default.
• W3173977892 cites W2214621962 @default.
• W3173977892 cites W2465092116 @default.
• W3173977892 cites W2604689121 @default.
• W3173977892 cites W2620746860 @default.
• W3173977892 cites W2620798309 @default.
• W3173977892 cites W2791535250 @default.
• W3173977892 cites W2792086148 @default.
• W3173977892 cites W2799931007 @default.
• W3173977892 cites W2897236707 @default.
• W3173977892 cites W2905423278 @default.
• W3173977892 cites W2911490798 @default.
• W3173977892 cites W2921268519 @default.
• W3173977892 cites W2937483840 @default.
• W3173977892 cites W2947014957 @default.
• W3173977892 cites W2947893479 @default.
• W3173977892 cites W2975895768 @default.
• W3173977892 doi "https://doi.org/10.1158/1078-0432.ccr-21-0685" @default.
• W3173977892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34187853" @default.
• W3173977892 hasPublicationYear "2021" @default.
• W3173977892 type Work @default.
• W3173977892 sameAs 3173977892 @default.
• W3173977892 citedByCount "4" @default.
• W3173977892 countsByYear W31739778922021 @default.
• W3173977892 countsByYear W31739778922022 @default.
• W3173977892 countsByYear W31739778922023 @default.
• W3173977892 crossrefType "journal-article" @default.
• W3173977892 hasAuthorship W3173977892A5001842263 @default.
• W3173977892 hasAuthorship W3173977892A5014617881 @default.
• W3173977892 hasAuthorship W3173977892A5027261034 @default.
• W3173977892 hasAuthorship W3173977892A5032708784 @default.
• W3173977892 hasAuthorship W3173977892A5034681607 @default.
• W3173977892 hasAuthorship W3173977892A5044156541 @default.
• W3173977892 hasAuthorship W3173977892A5047739980 @default.
• W3173977892 hasAuthorship W3173977892A5048994559 @default.
• W3173977892 hasAuthorship W3173977892A5063560933 @default.
• W3173977892 hasAuthorship W3173977892A5076875343 @default.
• W3173977892 hasBestOaLocation W31739778921 @default.
• W3173977892 hasConcept C121608353 @default.
• W3173977892 hasConcept C126322002 @default.
• W3173977892 hasConcept C126894567 @default.
• W3173977892 hasConcept C143998085 @default.
• W3173977892 hasConcept C2775908122 @default.
• W3173977892 hasConcept C2777783956 @default.
• W3173977892 hasConcept C2777899217 @default.
• W3173977892 hasConcept C2780192828 @default.
• W3173977892 hasConcept C2780737065 @default.
• W3173977892 hasConcept C2781190966 @default.
• W3173977892 hasConcept C509974204 @default.
• W3173977892 hasConcept C71924100 @default.
• W3173977892 hasConceptScore W3173977892C121608353 @default.
• W3173977892 hasConceptScore W3173977892C126322002 @default.
• W3173977892 hasConceptScore W3173977892C126894567 @default.
• W3173977892 hasConceptScore W3173977892C143998085 @default.
• W3173977892 hasConceptScore W3173977892C2775908122 @default.
• W3173977892 hasConceptScore W3173977892C2777783956 @default.
• W3173977892 hasConceptScore W3173977892C2777899217 @default.
• W3173977892 hasConceptScore W3173977892C2780192828 @default.
• W3173977892 hasConceptScore W3173977892C2780737065 @default.
• W3173977892 hasConceptScore W3173977892C2781190966 @default.
• W3173977892 hasConceptScore W3173977892C509974204 @default.
• W3173977892 hasConceptScore W3173977892C71924100 @default.
• W3173977892 hasIssue "16" @default.
• W3173977892 hasLocation W31739778921 @default.
• W3173977892 hasLocation W31739778922 @default.
• W3173977892 hasLocation W31739778923 @default.

• next